These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15177484)

  • 1. [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Moorman AR; Gessi S; Merighi S; Varani K; Borea PA
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3607-10. PubMed ID: 15177484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20.
    Gessi S; Varani K; Merighi S; Cattabriga E; Pancaldi C; Szabadkai Y; Rizzuto R; Klotz KN; Leung E; Mac Lennan S; Baraldi PG; Borea PA
    Mol Pharmacol; 2005 Jun; 67(6):2137-47. PubMed ID: 15788741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors.
    Varani K; Gessi S; Merighi S; Vincenzi F; Cattabriga E; Benini A; Klotz KN; Baraldi PG; Tabrizi MA; Lennan SM; Leung E; Borea PA
    Biochem Pharmacol; 2005 Nov; 70(11):1601-12. PubMed ID: 16219300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
    Tabrizi MA; Baraldi PG; Preti D; Romagnoli R; Saponaro G; Baraldi S; Moorman AR; Zaid AN; Varani K; Borea PA
    Bioorg Med Chem; 2008 Mar; 16(5):2419-30. PubMed ID: 18077171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists.
    Kalla RV; Elzein E; Perry T; Li X; Palle V; Varkhedkar V; Gimbel A; Maa T; Zeng D; Zablocki J
    J Med Chem; 2006 Jun; 49(12):3682-92. PubMed ID: 16759111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors.
    Ji X; Kim YC; Ahern DG; Linden J; Jacobson KA
    Biochem Pharmacol; 2001 Mar; 61(6):657-63. PubMed ID: 11266650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists.
    Elzein E; Kalla R; Li X; Perry T; Parkhill E; Palle V; Varkhedkar V; Gimbel A; Zeng D; Lustig D; Leung K; Zablocki J
    Bioorg Med Chem Lett; 2006 Jan; 16(2):302-6. PubMed ID: 16275090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
    Varani K; Merighi S; Gessi S; Klotz KN; Leung E; Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Borea PA
    Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines.
    Kalla RV; Elzein E; Perry T; Li X; Gimbel A; Yang M; Zeng D; Zablocki J
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1397-401. PubMed ID: 18226896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A₂B adenosine receptor antagonists.
    Baraldi PG; Baraldi S; Saponaro G; Preti D; Romagnoli R; Piccagli L; Cavalli A; Recanatini M; Moorman AR; Zaid AN; Varani K; Borea PA; Tabrizi MA
    J Med Chem; 2012 Jan; 55(2):797-811. PubMed ID: 22148859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity.
    Bevan N; Butchers PR; Cousins R; Coates J; Edgar EV; Morrison V; Sheehan MJ; Reeves J; Wilson DJ
    Eur J Pharmacol; 2007 Jun; 564(1-3):219-25. PubMed ID: 17382926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
    Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
    ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Preti D; Zaid AN; Saponaro G; Tabrizi MA; Baraldi S; Romagnoli R; Moorman AR; Varani K; Cosconati S; Di Maro S; Marinelli L; Novellino E; Borea PA
    J Med Chem; 2011 Jul; 54(14):5205-20. PubMed ID: 21675777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.
    Borrmann T; Hinz S; Bertarelli DC; Li W; Florin NC; Scheiff AB; Müller CE
    J Med Chem; 2009 Jul; 52(13):3994-4006. PubMed ID: 19569717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors.
    Baraldi PG; Cacciari B; Romagnoli R; Varani K; Merighi S; Gessi S; Borea PA; Leung E; Hickey SL; Spalluto G
    Bioorg Med Chem Lett; 2000 Feb; 10(3):209-11. PubMed ID: 10698437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A structural study of new potent and selective antagonists to the A2B adenosine receptor.
    Ferretti V; Pretto L; Tabrizi MA; Bertolasi V
    Acta Crystallogr B; 2005 Oct; 61(Pt 5):569-76. PubMed ID: 16186657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors.
    Stewart M; Steinig AG; Ma C; Song JP; McKibben B; Castelhano AL; MacLennan SJ
    Biochem Pharmacol; 2004 Jul; 68(2):305-12. PubMed ID: 15194002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-affinity relationships of adenosine A2B receptor ligands.
    Beukers MW; Meurs I; Ijzerman AP
    Med Res Rev; 2006 Sep; 26(5):667-98. PubMed ID: 16847822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor.
    Klotz KN; Falgner N; Kachler S; Lambertucci C; Vittori S; Volpini R; Cristalli G
    Eur J Pharmacol; 2007 Feb; 556(1-3):14-8. PubMed ID: 17126322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.